Aurora Cannabis Shareholders Approve Board as Fiscal 2026 Results Beat Outlook
Aurora Cannabis shareholders approved the board as the company reported fiscal 2026 results that exceeded guidance, according to CEO Martin. Net revenue rose 11% to C$321 million, adjusted EBITDA increased 32% to C$54 million, and adjusted gross margin reached 64%. Aurora ended with C$165 million cash and no debt, and outlined fiscal 2027 international growth plans.
How this was made
The 30-second read
Why it matters
Traders can use the quantified fiscal beat (revenue, adjusted EBITDA, margins) and the expectation of sequentially higher Q2 revenue and adjusted EBITDA to reassess near-term earnings trajectory. The main counterweight is policy-driven uncertainty in Canada and execution risk around the consumer exit, partially offset by international growth plans and EU GMP capacity from Safari Flower.
Market read
Quantified beat versus guidance plus a sequential Q2 improvement expectation is a concrete catalyst for ACB positioning, while Canadian policy and consumer exit risks remain the key swing factors for forward estimates.
What to watch
The article does not quantify the magnitude/timing of Canadian consumer exit costs, nor does it provide updated full-year fiscal 2027 guidance ranges, leaving uncertainty around how much of the international offset will materialize.
Background
Aurora Cannabis’ CEO comments following formal business at a shareholder meeting, covering fiscal 2026 performance and fiscal 2027 priorities including international expansion and a Canadian consumer business exit.
Ticker impact
Aurora reported fiscal 2026 net revenue of C$321M (+11% YoY) and adjusted EBITDA of C$54M (+32% YoY), beating guidance high end.
Likely near-term positive bias for ACB on the beat and forward sequential growth expectation, tempered by uncertainty around Canadian consumer business exit.
The article provides multiple quantified beats (revenue, adjusted EBITDA, margins) and a forward-looking statement for Q2 sequential improvement, which are actionable for traders. However, it does not provide new valuation, revised full-year guidance, or deal terms beyond a prior acquisition reference, limiting conviction.
Market effects
Reinforces the medical cannabis theme that GMP-certified international capacity and margin discipline can translate into improved EBITDA, potentially supporting sector sentiment.
Highlights Germany and Poland as key growth markets, which may influence regional peers’ read-through on demand and pricing power.
Emphasizes EU GMP capacity and export positioning, relevant to cross-border medical cannabis supply chains in Europe and Australia.
Counterpoint
The fiscal beat may not fully offset upcoming Canadian medical/cannabis policy changes and the planned exit from the lower-margin Canadian consumer business, which could pressure future consolidated margins.
Key entities
- companyAurora Cannabis Inc
Canadian licensed producer of medical and consumer cannabis; reported fiscal 2026 results above outlook and outlined fiscal 2027 priorities.
- companySafari Flower Company
EU GMP-certified cannabis cultivator and manufacturer acquired by Aurora, cited as adding EU GMP capacity and being accretive to adjusted EBITDA in Q1 fiscal 2027.
